

## **Grant Opportunity - Call for Applications**

### **DOM Innovation Pilot Grant 2017**

#### **Department of Medicine Innovation Program**

#### **Massachusetts General Hospital-Partners**

The Department of Medicine Innovation Program (MIP) is an initiative within the DOM charged with accelerating the development and introduction of broadly applicable innovative ideas and cost effective technologies into the patient/provider community both within and outside of the MGH community. Supported work includes projects in IT/digital health, care delivery and novel device/drug approaches. The Medicine Innovation Program works to develop an active community that supports grass roots innovation, incubation and development of winning ideas and transformative products for our patients.

**Call for applications:** *MIP calls for applications that represent the potential to fundamentally change the way we approach, diagnose or treat medical disease.* Projects must demonstrate a new way of thinking about an existing challenge and define a pathway such that via MIP funding they will have investigated fundamental concepts about their idea. If successful, PI's supported by the MIP program will take their project to clear proof of concept. At the completion of tenure with the MIP program, the solution should be ready for subsequent grant funding, local deployment/use or partnership with an outside entity.

Examples of prior winning applications include:

- Light based therapy for the treatment of urinary tract infections: Proof of concept experiments to validate the underlying hypothesis
- New drug for the treatment of hypoparathyroidism: Funding for Phase I clinical trials

Applicants to previous year's RFP that have made significant interval progress on their project are encouraged to re-apply.

#### **Requirements for participation in the Medicine Innovation Program:**

The Medicine Innovation Program works closely with selected Principal Investigators to advance their work through mutually agreed upon timelines and deliverables established at the start of the program. In addition to monetary resources, we provide infrastructure support to facilitate relevant project management, consultant input (regulatory, tech build, etc), navigation through the MGH administrative infrastructure, and sufficient business or scientific development such that the project is highly likely to be successful in finding follow – on funding at the completion of the Medicine Innovation Program. The expected tenure of a project in the Medicine Innovation Program is 12-18 months.

*Key requirements to participate:*

- Primary PI resides in the Department of Medicine
- Completion of accurate timeline, milestones and budget at the initiation of the grant/program
- Meetings on an as needed basis with the MIP team to ensure project success (to be determined by PI and MIP team)
- Quarterly updates to MIP advisory board as to project progress
- Accurate and timely updates to MIP team as to project developments

**For more details please see our website at:**

<http://www.massgeneral.org/medicine/MIP-about.aspx>

**The 2017 RFP is looking for projects in 2 broad categories:**

**1. General Innovation:** Any project that has the potential to transform the way we deliver patient care. The project may be a process, device, research application, digital/IT application or drug that is under development. The winning applicant must describe how grant dollars and resource support from MIP will move the project forward towards a sustainable enterprise.

Specific subcategories and requirements include:

*Process:* Any process under development that through its further refinement, implementation or adoption can improve/transform the process of care for MGH patients. The team leader for the process innovation must have clinical or administrative duties in the area in which the process is to be applied.

*Device/Technology/IT:* Any device, technology or IT application currently under development and that has the potential to transform care, that with MIP funding could move to proof of concept development. For any application requiring testing on human subjects, an approved IND and/or IRB when appropriate must be in place at the time of the grant award. Any intellectual property related to the device or technology must be owned solely or in part by Partners Healthcare.

*Drug:* Any drug currently under development, that through MIP funding could move closer to commercialization and external partnering. If funds are to be used for clinical trials, an approved IND and/or IRB when appropriate must be in place at the time of the grant award. Any intellectual property related to the drug must be owned solely or in part by Partners Healthcare.

*Digital Health:* This path seeks to support ideas that will apply modern digital technologies to improve an aspect of healthcare. Digital health tools include (but are not limited to) the web, mobile devices and applications, patient facing devices used in the home, data analytics and wearables. In addition to building novel technology, applications that augment existing technologies to meet an unmet need encouraged to apply.

## **2. Artificial Intelligence in Medicine:**

The DOM Innovation Program actively seeks projects that explore opportunities to further enhance physician effectiveness, patient diagnosis/treatment or reduction of physician administrative burden via enhanced decision support/artificial intelligence. Eligible projects must currently have or the reasonable ability to access to required data at the time of application to be considered.

**Eligibility:** Any member of the MGH Department of Medicine may apply. Multi-departmental or cross institutional teams are welcome to apply, however the team leader must be from the MGH DOM. If the project has trainee involvement, the PI must be a member of MGH faculty.

**Funds available:** \$30,000 – 50,000 direct support, per award depending on project need, scope and deliverables. Investigators are asked to only request sufficient funds for project success. Monies will be given as needed as defined by the project but are not to include FTE support.

Up to 2 awards will be made in 2017. Based on success, progress, deliverables, significance, pilot projects may be eligible to apply for subsequent support.

**Application Process:**

Applications will be solicited in end January and triaged by the membership of the Innovation Program to a series of finalists. All finalists will be invited to present their concepts in person to the group for feedback and selection of the winning ideas.

*Application Announcement: Monday, January 30, 2017*

***Application deadline: 5 pm, Friday March 10, 2017***

*Selected Finalists Invited to Present to DOM Innovation Program: Spring 2017*

*Awards Announced: Late Spring 2017*

Christiana Iyasere, MD, MBA, Director, Medicine Innovation Program

Mark C Poznansky, MD, PhD, Co-Director, Medicine Innovation Program

Samantha Stabile, BS, Program Manager

## Application requirements

4 page (maximum) application (12 point Times New Roman font with 0.5 inch margins). Must include the following sections:

- Project Title
- Project domain (may choose more than one): general innovation, artificial intelligence
- Project leader and contact information
- Institution, Department
- Team Members
- Current institutional, grant or private industry support for project if any
- Abstract (200 word maximum; understandable to general audience)
- Specific aims and deliverable(s) for 12 month project period
- Background and Significance
- Preliminary results (if applicable)
- Timeline, milestones
- Intellectual property (if applicable)
- Budget (if more than 30,000 -50,000 are needed for this project, please outline how these monies will be used to move the project forward overall and plans for subsequent funding)
- If successful, describe next steps in development plan
- Key next steps in follow-on funding at completion of the MIP program, to include specific grants that will be applied for (name grant and timing of grant application), tentative 3<sup>rd</sup> party partners (when applicable)

Applications must be submitted electronically as a single pdf document (see below).

**Selection:** Projects will be selected based on impact, significance, investigative team and environment, innovation, approach, deliverables, time-line, and the ability to move a potential idea forward along a clearly defined development pathway. Selected projects must meet all pertinent institutional requirements (biosafety, animal approval, IRB approval; if applicable) prior to issuance of award. When applicable, PIs must meet with representatives of the MGH-Partners licensing office and the DOM Innovation Program to discuss development plans and potential partnerships prior to issuance of award.

Finally, the DOM Innovation Program will include a mentoring/networking component to this program in which assistance will be offered to the PI's team to assist in the acceleration of the development and commercialization of supported technologies.

**Applications must be submitted electronically as a single PDF document to the e-mail address:**

[medicineinnovationprogram@partners.org](mailto:medicineinnovationprogram@partners.org)

***For more information please contact Christiana Iyasere, MD, MBA Director, or Mark Poznansky, MD, PhD, Co-Director; Medicine Innovation Program at:***

[medicineinnovationprogram@partners.org](mailto:medicineinnovationprogram@partners.org)